Clinical trials: High Risk Prostate Cancer
High-risk Prostate Cancer, Neoadjuvant Therapy
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr.
- Trial name
- NCT05223582
- Testing
- Abiraterone acetate, Fluzoparib, Prednisone
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
- Trial name
- NCT04869371
- Testing
- Docetaxel injection, Triptorelin Pamoate for Injectable Suspension, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hongqian Guo
Neoadjuvant Therapy, High Risk Prostate Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
- Conditions
- Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
- Trial name
- NCT05406999
- Testing
- ADT, Abiraterone Acetate, Prednisolone tablets
- Where
- China
- Volunteers
- 900 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer, Stereotactic Body Radiotherapy
A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer
Stereotactic body radiotherapy (SBRT) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(PCa).
- Conditions
- Prostate Cancer, Stereotactic Body Radiotherapy, High-risk, Efficacy
- Trial name
- NCT05430737
- Testing
- stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
High Risk Prostate Cancer
Novel Imaging in Staging of Primary Prostate Cancer
Prostate cancer (PC) is the most common cancer among men and one quarter of diagnosed PC are metastatic at the time of diagnosis.
- Trial name
- PROSTAGE (NCT03537391)
- Testing
- Whole body contrast enhanced computer tomography, 99mTC-HMDP planar bone scintigraphy (BS), 99mTc-HMDP single photon emission computer tomography/computer tomography
- Where
- Finland
- Volunteers
- 80 people
- Sponsor
- Turku University Hospital
Prostate Adenocarcinoma, Prostate Cancer
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
- Trial name
- NCT02268175
- Testing
- Enzalutamide, Abiraterone Acetate, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Dana-Farber Cancer Institute
Neoadjuvant Therapy \High Risk Prostate Cancer
Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A randomized, controlled, double-blind…
- Trial name
- NCT05076851
- Testing
- Proxalutamide
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Hongqian Guo
High-risk Prostate Cancer, Prostate Cancer
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+ valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in…
- Trial name
- NCT03541928
- Testing
- HSV-Tk, Valacyclovir, Bicalutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Methodist Hospital Research Institute
High Risk Prostate Cancer
Neoadjuvant BKM120 in High-risk Prostate Cancer
This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer. Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the prostate to confirm high-risk disease and…
- Trial name
- NCT01695473
- Testing
- BKM120
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Won Kim
High-risk Prostate Cancer, Prostate Cancer
Ga-68-PSMA-11 in High-risk Prostate Cancer
This will be an open-label, single-arm, rater-blinded, multicenter, diagnostic phase 1/2 study to assess safety and diagnostic performance of Ga-68-PSMA-11 positron emission tomography / computer tomography (PET/CT) imaging to…
- Conditions
- High-risk Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic, Lymphnode Metastasis
- Trial name
- NCT03362359
- Testing
- Ga-68-PSMA-11
- Where
- 8 sites in Austria, Germany
- Volunteers
- 173 people
- Sponsor
- German Cancer Research Center
Patients With High-risk Prostate Cancer
Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer…
- Trial name
- NCT01800058
- Where
- 3 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.
The general aim of the study is to describe the use of elective pelvic node irradiation (ENI) in Italy, in patients with intermediate/high/very high-risk prostate cancer patients submitted to adjuvant or radical Radiation Therapy…
- Trial name
- PRO-EPI (NCT03340272)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
HIGH RISK PROSTATE CANCER
Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca
HDR brachytherapy in conjunction with pelvic SABR in high tier intermediate and high risk prostate cancer patients can provide a safe and effective means of radiotherapy dose escalation.
- Trial name
- SPARE (NCT04236752)
- Testing
- Stereotactic Ablative Body Radiation (SBRT)
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Sunnybrook Health Sciences Centre
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
High Risk Prostate Cancer
Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer
Considering the promising results with hypofractionated in low and intermediate risk prostate cancer, our proposal is to translate this experience to patients with high risk prostate cancer.
- Trial name
- NCT02107287
- Testing
- IMRT Technique
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Sergio Faria